Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in pediatric progressive, recurrent, and refractory sarcoma
NCT04659733Phase 1Unknown
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of anlotinib in sarcoma. Primary endpoint: Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
anlotinib
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT04659733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659733.